China suspended the use of a BeiGene cancer drug, Abraxane. BeiGene, which gets the drug from Bristol-Myers, said the problem stems from a Bristol-Myers contract manufacturing plant in the U.S ...

In January, headlines trumpeted the release of a new chemotherapy drug for breast cancer called Abraxane. Technically, Abraxane isn't a new drug -- it's an exciting new way of delivering an ...

He also invented Abraxane, a cancer treatment that is expected to reach $1 billion in sales by 2016. Soon-Shiong launched NantWorks, an ecosystem of companies focused on global health information ...

Bristol-Myers Squibb Company (NYSE: BMY) reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus ...

The drug, Abraxane, was approved by the FDA in 2005 and the European equivalent in 2008 for the treatment of breast cancer when chemotherapy was not working. By 2009, Abraxane generated $315 ...

In February, Sorrento Therapeutics (OTC:SRNEQ) started U.S. bankruptcy filings for the year after its plans to introduce a ...

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ...

and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company ...

The upcoming report from Bristol Myers Squibb (BMY) is expected to reveal quarterly loss of $4.51 per share, indicating a decline of 320% compared to the year-ago period. Analysts forecast revenues of ...

as well as improving its financial position despite increased competition from generic versions of its blockbusters such as Revlimid and Abraxane.

The incremental benefits in median survival have been modest in the past 11 years with the recent approval of Onivyde in the NALIRIFOX regimen demonstrating a 1.9 month survival benefit compared to ...